Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Christian Klemt Biography and Net Worth

CFO of uniQure

Mr. Christian Klemt has served as Chief Accounting Officer since August 2017. In 2020 he was named General Manager of our Amsterdam office.

Since joining uniQure in 2015, Mr. Klemt has transformed the Finance and Accounting functions at uniQure, dramatically improved the internal control environment, and enhanced the financial planning and analysis functions. He also oversaw the Company's transition to a domestic U.S. filer and conversion to U.S. Generally Accepted Accounting Principles.

Mr. Klemt holds a Master's degree in Business Administration from the University of Muenster, Germany and is qualified as a German Certified Public Accountant and Tax Advisor.

What is Christian Klemt's net worth?: The estimated net worth of Christian Klemt is at least $2.83 million as of December 9th, 2024. Mr. Klemt owns 166,713 shares of uniQure stock worth more than $2,830,787 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Klemt may own. Additionally, Mr. Klemt receives an annual salary of $575,460.00 as CFO at uniQure. Learn More about Christian Klemt's net worth.
How old is Christian Klemt?: Mr. Klemt is currently 51 years old. There are 4 older executives and no younger executives at uniQure. The oldest executive at uniQure is Dr. Walid Abi-Saab M.D., Chief Medical Officer, who is 59 years old. Learn More on Christian Klemt's age.
What is Christian Klemt's salary?: As the CFO of uniQure, Mr. Klemt earns $575,460.00 per year. There are 2 executives that earn more than Mr. Klemt. The highest earning executive at uniQure is Mr. Matthew Craig Kapusta, CEO & Executive Director, who commands a salary of $1,020,000.00 per year. Learn More on Christian Klemt's salary.
How do I contact Christian Klemt?: The corporate mailing address for Mr. Klemt and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Christian Klemt's contact information.
Has Christian Klemt been buying or selling shares of uniQure?: Over the course of the past ninety days, Christian Klemt has sold $13,559.80 of uniQure stock. Most recently, Christian Klemt sold 1,796 shares of the business's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.55, for a transaction totalling $13,559.80. Following the completion of the sale, the chief financial officer now directly owns 166,713 shares of the company's stock, valued at $1,258,683.15. Learn More on Christian Klemt's trading history.
Who are uniQure's active insiders?: uniQure's insider roster includes Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Christian Klemt (CFO), and Alexander Kuta, III (VP). Learn More on uniQure's active insiders.
Are insiders buying or selling shares of uniQure?: In the last twelve months, insiders at the biotechnology company sold shares 8 times. They sold a total of 66,928 shares worth more than $421,017.91. The most recent insider tranaction occured on December, 9th when CEO Matthew C Kapusta sold 3,418 shares worth more than $26,079.34. Insiders at uniQure own 4.7% of the company. Learn More about insider trades at uniQure.
Information on this page was last updated on 12/9/2024.

Christian Klemt Insider Trading History at uniQure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/9/2024	Sell	1,796	$7.55	$13,559.80	166,713
2/26/2024	Sell	15,906	$6.38	$101,480.28	116,948
6/16/2023	Sell	1,587	$18.94	$30,057.78	132,854
3/7/2023	Sell	986	$21.36	$21,060.96	134,441
12/9/2022	Sell	2,608	$22.35	$58,288.80	107,180
6/16/2022	Sell	1,687	$13.20	$22,268.40	104,688
2/28/2022	Sell	4,075	$16.80	$68,460.00
1/26/2022	Sell	3,963	$18.03	$71,452.89
9/21/2021	Sell	2,400	$38.00	$91,200.00
1/26/2021	Sell	952	$39.00	$37,128.00	56,066
4/24/2020	Sell	2,250	$60.00	$135,000.00	59,268
3/4/2020	Sell	15,750	$52.29	$823,567.50	72,768
1/28/2020	Sell	11,975	$61.47	$736,103.25	45,597
4/16/2019	Sell	1,546	$57.18	$88,400.28	54,539
1/28/2019	Sell	1,479	$31.29	$46,277.91	56,085
1/3/2019	Sell	5,739	$27.91	$160,175.49	40,000
1/3/2018	Sell	5,093	$20.13	$102,522.09

Christian Klemt Buying and Selling Activity at uniQure

uniQure Company Overview

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Today's Range

Now: $16.98

$15.35

$17.58

50 Day Range

MA: $8.13

$5.56

$17.40

2 Week Range

Now: $16.98

$3.73

$17.71

Volume

2,053,596 shs

Average Volume

1,659,723 shs

Market Capitalization

$827.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.

Christian Klemt Biography and Net Worth

What is Christian Klemt's net worth?

How old is Christian Klemt?

What is Christian Klemt's salary?

How do I contact Christian Klemt?

Has Christian Klemt been buying or selling shares of uniQure?

Who are uniQure's active insiders?

Are insiders buying or selling shares of uniQure?